Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant.

abstract：:At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchos...

journal_title：Bone marrow transplantation

authors： Humar A,O'Rourke K,Lipton J,Messner H,Meharchand J,Mahony J,Walker I,Wasi P,McGeer A,Moussa G,Chua R,Mazzulli T

更新日期：1999-01-01 00:00:00

abstract：:The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

journal_title：Bone marrow transplantation

authors： Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

更新日期：1993-01-01 00:00:00

abstract：:We examined whether pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is capable of improving thrombocytopenia and promoting thrombopoietic reconstitution following lethal irradiation and bone marrow transplantation (BMT) in mice. Immediately after receiving 10 Gy whole body irradia...

journal_title：Bone marrow transplantation

authors： Kabaya K,Shibuya K,Torii Y,Nitta Y,Ida M,Akahori H,Kato T,Kusaka M,Miyazaki H

更新日期：1996-12-01 00:00:00

abstract：:We report the case of a 4-year-old female with high-risk ALL in first CR who received a BMT from an 11-month-old matched sibling treated with G-CSF in order to obtain an adequate number of mononuclear cells in a limited volume of bone marrow. The absence of toxicity, efficacy of the procedure and quality of the post-t...

journal_title：Bone marrow transplantation

authors： Pession A,Locatelli F,Prete A,Pigna A,Magrini E,Conte R,Rosito P,Paolucci G

更新日期：1996-03-01 00:00:00

abstract：:Ten patients with Ph+ chronic myeloid leukemia (CML) were treated with idarubicin, cytarabine and etoposide followed by G-CSF to harvest Ph-negative progenitor cells. Six were in first chronic phase (CP1), and four beyond CP1. Between two and six aphereses (median 3, total 36) were performed starting 9-26 days (median...

journal_title：Bone marrow transplantation

authors： Mehta J,Mijović A,Powles R,Pagliuca A,Singhal S,Czepulkowski B,Swansbury GJ,Treleaven J,Mufti GJ

更新日期：1996-01-01 00:00:00

abstract：:The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and a...

journal_title：Bone marrow transplantation

authors： Meletis J,Papavasiliou S,Yataganas X,Vavourakis S,Konstantopoulos K,Poziopoulos C,Samarkos M,Michali E,Dalekou M,Eliopoulos G

更新日期：1994-11-01 00:00:00

abstract：:Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, ...

journal_title：Bone marrow transplantation

authors： Le Bris Y,Guillaume T,Ménard A,Illiaquer M,Martin J,Malard S,Duquesne A,Peterlin P,Debord C,Robillard N,Eveillard M,Wuillème S,Delaunay J,Mohty M,Garnier A,Moreau P,Béné MC,Chevallier P

更新日期：2017-06-01 00:00:00

abstract：:The purpose of this study was to evaluate the effect of partial renal shielding used in conjunction with total body irradiation (TBI) on the incidence of bone marrow transplantation nephropathy (BMT Np) seen as a late sequelae after transplantation. Of 402 patients who have undergone bone marrow transplantation (BMT) ...

journal_title：Bone marrow transplantation

authors： Lawton CA,Cohen EP,Murray KJ,Derus SW,Casper JT,Drobyski WR,Horowitz MM,Moulder JE

更新日期：1997-12-01 00:00:00

abstract：:Among 145 consecutive patients undergoing bone marrow transplantation (BMT) for leukemia or aplastic anemia. 30 (21%) were found positive for hepatitis B surface antigen (HBsAg) in serum either before or after BMT. Their serologic profile and clinical outcome are described. Nine out of 30 patients were HBsAg positive ...

journal_title：Bone marrow transplantation

authors： Locasciulli A,Bacigalupo A,Van Lint MT,Chemello L,Pontisso P,Occhini D,Uderzo C,Shulman HM,Portmann B,Marmont AM

更新日期：1990-07-01 00:00:00

abstract：:Forty-six children with juvenile myelomonocytic leukemia (JMML) diagnosed between 1978 and 1993 in 12 centers were retrospectively studied. There is no evidence that any conventional treatment influences the long-term evolution of JMML. Among 28 patients treated without bone marrow transplantation (BMT), 26 died (medi...

journal_title：Bone marrow transplantation

authors： Lutz P,Zix-Kieffer I,Souillet G,Bertrand Y,Dhooge C,Rubie C,Mazingue F,Marguerite F,Machinaud-Lacroix F,Rialland X,Plouvier E,Behar C,Vilmer E,Philippe N,Otten J

更新日期：1996-12-01 00:00:00

abstract：:In the original version of this article, the mention of 'ifosfamide 1500 mg/m2 days 1-3' should, in fact, read 'ifosfamide 1500 mg/m2 bd days 1-3'. This has now been updated in the original version of the article. ...

journal_title：Bone marrow transplantation

authors： Phillips EH,Lannon MM,Lopes A,Chadwick H,Jones G,Sieniawski M,Davies A,Wood K,Clifton-Hadley L,Smith P,Lawrie A,Chadwick N,Lennard AL

更新日期：2020-04-01 00:00:00

abstract：:This was an open-label, single-center, phase II study of 20 patients with multiple myeloma who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT. The aim was to assess the safety and efficacy of plerixafor for stem cell mob...

journal_title：Bone marrow transplantation

authors： Tricot G,Cottler-Fox MH,Calandra G

更新日期：2010-01-01 00:00:00

abstract：:The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in pati...

journal_title：Bone marrow transplantation

authors： Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

更新日期：2012-02-01 00:00:00

abstract：:Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

journal_title：Bone marrow transplantation

authors： Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

更新日期：2011-01-01 00:00:00

abstract：:ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring plasma IgM and IgG antibodies against these antigens are ubiquitous. Nonetheless, the ABO blood group system is widely ignored ...

journal_title：Bone marrow transplantation

authors： Heal JM,Liesveld JL,Phillips GL,Blumberg N

更新日期：2005-11-01 00:00:00

abstract：:Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT). We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of N...

journal_title：Bone marrow transplantation

authors： Dowling MR,Li S,Dey BR,McAfee SL,Hock HR,Spitzer TR,Chen YB,Ballen KK

更新日期：2018-02-01 00:00:00

abstract：:Comprehensive programmes for BMT started in Hong Kong in 1990. As of September 1993, there are a total of 13 BMT beds in Government-funded University Hospitals performing about 110 transplants per year or 18 transplants per million population per year. So far, 194 transplants were performed: allogeneic BMT (72.2%), au...

journal_title：Bone marrow transplantation

authors： Chiu EK,Yuen P,Chan TK

更新日期：1994-06-01 00:00:00

abstract：:The influence of the CFU-GM content of donor marrow on the outcome of allogeneic marrow transplantation (BMT) has been debated. We now report 38 patients (25 acute leukemias, 10 chronic myeloid leukemias, two myeloma; 24 in first CR/CP and 14 in more advanced phases of their disease) undergoing unmanipulated HLA-ident...

journal_title：Bone marrow transplantation

authors： Bacigalupo A,Piaggio G,Podesta M,Figari O,Benvenuto F,Sogno G,Tedone E,Raffo MR,Grassia L,Ferrero R

更新日期：1995-02-01 00:00:00

abstract：:Using in situ hybridization with an X and Y chromosome probe mixture, 106 bone marrow samples from 38 patients with malignant and non-malignant hematological diseases who received sex-mismatched allogeneic hematopoietic progenitor cell transplants (PCT) in a single institution within short-term intervals (1, 3, 6, 12,...

journal_title：Bone marrow transplantation

authors： Ortega M,Escudero T,Caballín MR,Olivé T,Ortega JJ,Coll MD

更新日期：1999-07-01 00:00:00

abstract：:Binding and human complement-mediated T and B lymphocyte lysis were investigated in bone marrow samples obtained from 15 normal donors and 12 patients with a variety of malignant disorders undergoing marrow cryopreservation prior to autologous bone marrow transplantation. All marrow samples were obtained during remiss...

journal_title：Bone marrow transplantation

authors： Gazitt Y,Or R,Mumcuoglu M,Slavin S

更新日期：1987-12-01 00:00:00

abstract：:The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in t...

journal_title：Bone marrow transplantation

authors： Sweetenham JW

更新日期：2001-11-01 00:00:00

abstract：:Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is m...

journal_title：Bone marrow transplantation

authors： Sjöö F,Aschan J,Barkholt L,Hassan Z,Ringdén O,Hassan M

更新日期：2003-08-01 00:00:00

abstract：:To perform an optimal ex vivo bone marrow purge, it is necessary to concentrate the bone marrow progenitor cells and to eliminate both the red blood cells and the polymorphonuclear leucocytes. To achieve this goal which cannot be accomplished by using the Haemonetics model 30 alone, we used the Haemonetics model 30 an...

journal_title：Bone marrow transplantation

authors： Humblet Y,Lefebvre P,Jacques JL,Bosly A,Feyens AM,Sekhavat M,Agaliotis D,Symann M

更新日期：1988-01-01 00:00:00

abstract：:Bone marrow aspirates are composed of two cellular compartments, an abundant buffy coat suspension and a minor particulate fraction. The particulate fraction is routinely removed by filtration prior to transplantation in order to reduce the risk of embolism. This study shows that the filter-retained fraction includes ...

journal_title：Bone marrow transplantation

authors： Blazsek I,Delmas Marsalet B,Legras S,Marion S,Machover D,Misset JL

更新日期：1999-04-01 00:00:00

abstract：:We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underw...

journal_title：Bone marrow transplantation

authors： Hoppe BS,Moskowitz CH,Zhang Z,Maragulia JC,Rice RD,Reiner AS,Hamlin PA,Zelenetz AD,Yahalom J

更新日期：2009-06-01 00:00:00

abstract：:Allogeneic SCT remains the only potential cure for patients with thalassemia. However, most BMT candidates lack a suitable family donor and require an unrelated donor (UD). We evaluated whether BMT using UDs in high-risk adult thalassemia patients can offer a probability of cure comparable to that reported employing a...

journal_title：Bone marrow transplantation

authors： La Nasa G,Caocci G,Argiolu F,Giardini C,Locatelli F,Vacca A,Orofino MG,Piras E,Addari MC,Ledda A,Contu L

更新日期：2005-12-01 00:00:00

abstract：:SCT from an HLA-compatible sibling donor is an adoptive immunotherapy for cytokine-refractory, metastatic clear-cell renal cell cancer (RCC). However, the recent introduction of targeted therapy compounds has reduced the interest in this therapeutic strategy. We have reanalyzed our series with the aim to assess long-t...

journal_title：Bone marrow transplantation

authors： Bregni M,Bernardi M,Servida P,Pescarollo A,Crocchiolo R,Treppiedi E,Corradini P,Ciceri F,Peccatori J

更新日期：2009-08-01 00:00:00

abstract：:Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

journal_title：Bone marrow transplantation

authors： Landgren O,Devlin S,Boulad M,Mailankody S

更新日期：2016-12-01 00:00:00

abstract：:Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

journal_title：Bone marrow transplantation

authors： Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

更新日期：2020-10-01 00:00:00

abstract：:An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

journal_title：Bone marrow transplantation

authors： Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

更新日期：1998-01-01 00:00:00